New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - roxithromycin 150mg;   - coated tablet - 150 mg - active: roxithromycin 150mg   excipient: colloidal silicon dioxide glucose hyprolose hypromellose magnesium stearate maize starch povidone propylene glycol purified talc titanium dioxide water - adults roxithromycin is indicated for the treatment of the following types of mild to moderately severe infections caused by or likely to be caused by susceptible micro-organisms: · upper respiratory tract infection - acute pharyngitis, tonsillitis and sinusitis · dental infections · lower respiratory tract infection - acute bronchitis; acute exacerbations of chronic bronchitis and community acquired pneumonia · skin and skin structure infections · non-gonococcal urethritis. children roxithromycin 150 mg tablets are indicated for the treatment of the following mild to moderately severe infections in children caused by or likely to be caused by susceptible micro-organisms: acute pharyngitis, acute tonsillitis and impetigo. appropriate culture and sensitivity tests should be performed when necessary to determine organism susceptibility and thus treatment suitability. therapy with roxithromycin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued.

New Zealand - English - Medsafe (Medicines Safety Authority)

actavis new zealand limited - ranitidine hydrochloride 168mg equivalent to ranitidine 150 mg;   - film coated tablet - 150 mg - active: ranitidine hydrochloride 168mg equivalent to ranitidine 150 mg   excipient: croscarmellose sodium magnesium stearate microcrystalline cellulose opadry white ys-22-18096 purified water

New Zealand - English - Medsafe (Medicines Safety Authority)

aurobindo pharma nz limited - quetiapine fumarate 172.683mg equivalent to 150 mg quetiapine - film coated tablet - 150 mg - active: quetiapine fumarate 172.683mg equivalent to 150 mg quetiapine excipient: calcium hydrogen phosphate dihydrate colloidal silicon dioxide lactose monohydrate magnesium stearate microcrystalline cellulose opacode black s-1-17823 opadry yellow 03b82924 povidone purified talc sodium starch glycolate - acute and chronic psychoses, including schizophrenia.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - bicalutamide - oral tablet - 150mg

United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

city medical store - sole proprietorship l.l.c switzerland - 150's [(5's blister x 10) x 3] - capsule - 150 mg / capsule - malignant disease,immunosuppresion-cytotoxics

New Zealand - English - Medsafe (Medicines Safety Authority)

actavis new zealand limited - tramadol hydrochloride 150mg - modified release tablet - 150 mg - active: tramadol hydrochloride 150mg excipient: calcium hydrogen phosphate dihydrate colloidal silicon dioxide hyprolose magnesium stearate - relief of moderate to severe pain

New Zealand - English - Medsafe (Medicines Safety Authority)

centre for advanced medicine - disodium edetate 150 mg/ml (added as disodium edetate hydrous 166mg) - solution for injection - 150 mg/ml - active: disodium edetate 150 mg/ml (added as disodium edetate hydrous 166mg) excipient: hydrochloric acid sodium hydroxide water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

rex medical ltd - lamivudine 150mg; zidovudine 300mg;   - film coated tablet - 150mg/300mg - active: lamivudine 150mg zidovudine 300mg   excipient: colloidal silicon dioxide hypromellose magnesium stearate microcrystalline cellulose propylene glycol purified talc sodium starch glycolate titanium dioxide - zidovudine 300mg/lamivudine 150mg is indicated for the treatment of hiv infected adults and adolescents over the age of 12 years, with progressive immunodeficiency (cd4 = count = <500 cells/mm3).

United States - English - NLM (National Library of Medicine)

encube ethicals private limited - clobetasol propionate (unii: 779619577m) (clobetasol - unii:adn79d536h) - clobetasol propionate cream usp, 0.05% is super-high potency corticosteroid formulation indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. treatment beyond 2 consecutive weeks is not recommended, and the total dosage should not exceed 50 g /week because of the potential for the drug to suppress the hypothalamic-pituitary- adrenal (hpa) axis. use in pediatric patients under 12 years of age is not recommended. as with other highly active corticosteroids, therapy should be discontinued when control has been achieved. if no improvement is seen within 2 weeks, reassessment of the diagnosis may be necessary. clobetasol propionate cream usp, 0.05% is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparations.

United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

alphamed drug store saudi arabia - 150 ml polypropylene bag - infusion - 750mg/150ml - infections-antibacterial